The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
2022 Global patient survey: Reported experience of diagnosis, management, and burden of renal cell carcinomas.
 
Rachel H. Giles
Honoraria - Ipsen (Inst); Merck KGaA (Inst); Pfizer/EMD Serono (Inst)
 
Deborah Maskens
Honoraria - BMS Canada; Merck
Consulting or Advisory Role - Pfizer
 
Lorenzo Marconi
No Relationships to Disclose
 
Robin Martinez
No Relationships to Disclose
 
Karin Kastrati
Consulting or Advisory Role - Ipsen (Inst); Merck (Inst); Novartis (Inst)
 
Carlos Castro
No Relationships to Disclose
 
Juan Carlos Julian Mauro
No Relationships to Disclose
 
Robert Bick
No Relationships to Disclose
 
Margie Hickey
No Relationships to Disclose
 
Daniel Yick Chin Heng
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst)
 
James Larkin
Honoraria - Agence Unik; Bristol-Myers Squibb; Cambridge Healthcare research; Eisai; Incyte; Merck Serono; Novartis; Pfizer; RCGP; Royal College of Physicians; touchEXPERTS; touchIME; VJOncology
Consulting or Advisory Role - Agence Unik; Apple Tree Partners; Aptitude Health; AstraZeneca; Bristol-Myers Squibb; Calithera Biosciences; Debiopharm Group; eCancer; Eisai; EUSA Pharma; GlaxoSmithKline; Goldman Sachs; Incyte; Insel Gruppe; iOnctura; Ipsen; Merck Serono; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Ultimovacs
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline; Pierre Fabre; Roche/Genentech
 
Axel Bex
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
Speakers' Bureau - Eisai
Research Funding - Pfizer (Inst)
 
Eric Jonasch
Consulting or Advisory Role - aravive; Aveo; Calithera Biosciences; Eisai; Exelixis; Merck; NiKang Therapeutics; Novartis; Pfizer; Takeda
Research Funding - Arrowhead Pharmaceuticals (Inst); Merck; NiKang Therapeutics; Novartis
Travel, Accommodations, Expenses - Pfizer
 
Sara Jane Maclennan
No Relationships to Disclose
 
Michael A.S. Jewett
No Relationships to Disclose